These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17241182)

  • 1. Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study.
    de Vries F; Pouwels S; Lammers JW; Leufkens HG; Bracke M; Cooper C; van Staa TP
    J Intern Med; 2007 Feb; 261(2):170-7. PubMed ID: 17241182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of beta-2 agonists and risk of hip/femur fracture: a population-based case-control study.
    de Vries F; Pouwels S; Bracke M; Leufkens HG; Cooper C; Lammers JW; van Staa TP
    Pharmacoepidemiol Drug Saf; 2007 Jun; 16(6):612-9. PubMed ID: 16998945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of anti-depressants and the risk of fracture of the hip or femur.
    van den Brand MW; Pouwels S; Samson MM; van Staa TP; Thio B; Cooper C; Leufkens HG; Egberts AC; Verhaar HJ; de Vries F
    Osteoporos Int; 2009 Oct; 20(10):1705-13. PubMed ID: 19238308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopaminergic drugs and the risk of hip or femur fracture: a population-based case-control study.
    Arbouw ME; Movig KL; van Staa TP; Egberts AC; Souverein PC; de Vries F
    Osteoporos Int; 2011 Jul; 22(7):2197-204. PubMed ID: 20967420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study.
    Pouwels S; Lalmohamed A; Souverein P; Cooper C; Veldt BJ; Leufkens HG; de Boer A; van Staa T; de Vries F
    Osteoporos Int; 2011 Mar; 22(3):903-10. PubMed ID: 20585937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of bone fracture after long-term risperidone exposure is not increased compared to other atypical antipsychotics: A retrospective cohort study.
    Shen SP; Liu Y; Qiu H; Tsai KY; Wu HC; Liang WM; Shu M; Chou FH
    PLoS One; 2019; 14(9):e0221948. PubMed ID: 31487309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fracture risk with intermittent high-dose oral glucocorticoid therapy.
    De Vries F; Bracke M; Leufkens HG; Lammers JW; Cooper C; Van Staa TP
    Arthritis Rheum; 2007 Jan; 56(1):208-14. PubMed ID: 17195223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands.
    de Vries F; Souverein PC; Cooper C; Leufkens HG; van Staa TP
    Calcif Tissue Int; 2007 Feb; 80(2):69-75. PubMed ID: 17308987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.
    Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
    Osteoporos Int; 2016 May; 27(5):1709-18. PubMed ID: 26694595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study.
    Pouwels S; van Staa TP; Egberts AC; Leufkens HG; Cooper C; de Vries F
    Osteoporos Int; 2009 Sep; 20(9):1499-506. PubMed ID: 19156348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study.
    Amiche MA; Abtahi S; Driessen JHM; Vestergaard P; de Vries F; Cadarette SM; Burden AM
    Arch Osteoporos; 2018 Mar; 13(1):30. PubMed ID: 29552730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of high-dose intermittent systemic glucocorticoids and the risk of fracture in patients with chronic obstructive pulmonary disease.
    Oshagbemi OA; Burden AM; Shudofsky KN; Driessen JHM; Vestergaard P; Krings A; Franssen FME; van den Bergh J; de Vries F
    Bone; 2018 May; 110():238-243. PubMed ID: 29462672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
    Van Staa TP; Laan RF; Barton IP; Cohen S; Reid DM; Cooper C
    Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of alpha-blockers and the risk of hip/femur fractures.
    Souverein PC; Van Staa TP; Egberts AC; De la Rosette JJ; Cooper C; Leufkens HG
    J Intern Med; 2003 Dec; 254(6):548-54. PubMed ID: 14641795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of systemic glucocorticoids and the risk of major osteoporotic fractures in patients with sarcoidosis.
    Oshagbemi OA; Driessen JHM; Pieffers A; Wouters EFM; Geusens P; Vestergaard P; van den Bergh J; Franssen FME; de Vries F
    Osteoporos Int; 2017 Oct; 28(10):2859-2866. PubMed ID: 28638981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids.
    Vestergaard P; Rejnmark L; Mosekilde L
    Chest; 2007 Nov; 132(5):1599-607. PubMed ID: 17890464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of hip/femur fracture after stroke: a population-based case-control study.
    Pouwels S; Lalmohamed A; Leufkens B; de Boer A; Cooper C; van Staa T; de Vries F
    Stroke; 2009 Oct; 40(10):3281-5. PubMed ID: 19661475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort.
    Kim SY; Schneeweiss S; Katz JN; Levin R; Solomon DH
    J Bone Miner Res; 2011 May; 26(5):993-1001. PubMed ID: 21542002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fracture risk associated with systemic and topical corticosteroids.
    Vestergaard P; Rejnmark L; Mosekilde L
    J Intern Med; 2005 Apr; 257(4):374-84. PubMed ID: 15788008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of inhaled glucocorticoids and beta(2) agonists on vertebral fracture risk in COPD patients: the EOLO study.
    Gonnelli S; Caffarelli C; Maggi S; Guglielmi G; Siviero P; Rossi S; Crepaldi G; Nuti R;
    Calcif Tissue Int; 2010 Aug; 87(2):137-43. PubMed ID: 20567964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.